Company Overview of Acucela Inc.
Acucela Inc., a clinical-stage biotechnology company, focuses on developing new treatments for blinding eye diseases. It provides orally-delivered visual cycle modulation (VCM) therapies that target cells within the retina to protect visual acuity and used to treat devastating eye diseases, including dry age-related macular degeneration (AMD) that affect people worldwide; and non-VCM programs. The company was founded in 2002 and is based in Seattle, Washington.
1301 Second Avenue
Seattle, WA 98101-3805
Founded in 2002
Key Executives for Acucela Inc.
Acucela Inc. Key Developments
Similar Private Companies By Industry
|Stan’s Rodeo Ointment||United States|
|Research Essential Services, LLC||United States|
|Vector Medical Technologies, Inc.||United States|
|IDUN Pharmaceuticals, Inc.||United States|
|Beardsworth Consulting Group, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Greater Houston Partnership||United States|
Post a JobJobs
- Germany, PA | Life TechnologiesPosted: Nov 22
- Spring House, PA | Johnson & JohnsonPosted: Dec 05
- Boston, MA | Established HospitalPosted: Dec 06
- Frederick, MD | Computer Sciences Corporation (CSC)Posted: Dec 01
Sponsored Financial Commentaries
To contact Acucela Inc., please visit www.acucela.com. Company data is provided by Capital IQ. Please use this form to report any data issues.